CVAid Medical

CVAid focuses on the field of stroke telemedicine (telestroke), aiming to improve stroke diagnosis and spread its advanced technologies to save lives. The company offers a full-cycle stroke diagnosis and disease management platform, encompassing pre-hospital early diagnosis, in-hospital process management, and follow-up upon discharge from the hospital. The company's CVA-Flow is a comprehensive telestroke system that ensures early and accurate diagnosis of stroke by certified neurology teams using a standard smartphone and dedicated cloud servers. The CVA-Flow, supported by its artificial-intelligence module (CVA-Core), synchronizes all stroke stakeholders (e.g. patients, EMS, ER, stroke centers, medical teams, and management). CVAid uses a proprietary database of visual and auditory recordings of stroke patients, along with machine- and deep-learning tools, to create an all-in-one software solution that analyzes data in real time, providing neurologists with support tools to remotely diagnose patients without sacrificing quality.

CVAid Medical has raised $4M in total funding across 2 rounds. The company is currently at the A stage. Key investors include RAD BioMed, Phillips Ventures, Sanara Capital.

CVAid Medical was founded in 2018 by Danny Farin (Co-founder & Chairman), Oren Dror (Co-founder & CEO), Rotem Sivan-Hoffmann (Co-founder & CMO), Nadav Eichler (Co-founder & CTO).

CVAid Medical operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, Medical Decision Support, with core technologies in Data Storage, Cloud, Artificial Intelligence, Machine Learning. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers.

CVAid Medical is based in Raul Wallenberg Street 6, Tel Aviv-Yafo, Israel, Center District.